Brief: Mannkind Expands Patent Portfolio With New Clofazimine Formulation Patent
30/10/2023 10:41
Oct 30 (Reuters) - MannKind Corp MNKD.O :
* MANNKIND EXPANDS PATENT PORTFOLIO WITH NEW CLOFAZIMINE
FORMULATION PATENT
* MANNKIND CORP - DEVELOPMENT OF MNKD-101 (INHALED
CLOFAZIMINE)
CONTINUES FOR POTENTIAL TREATMENT OF NONTUBERCULOUS
MYCOBACTERIAL (NTM) LUNG DISEASE
* MANNKIND CORP - PATENT WILL EXPIRE ON JUNE 8, 2039.
Source text for Eikon: ID:nGNX5XCTSm
Further company coverage: MNKD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on MannKind
See all newsBrief: MannKind Enters Data-Rich Development Period With Completion Of Randomization In Phase 1B Inflo-1 Study And Enrollment Of First Patient In Phase 2 Inflo-2 Trial For Nintedanib Dpi In Patients With Ipf
U.S. STOCKS ON THE MOVE-Dell, Gap, Costco
MannKind rises after FDA approves inhaled insulin for children
US FDA approves MannKind's inhaled insulin for children (updated)
US FDA approves MannKind's inhaled insulin for children